Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EpCAM/anti-CD3 bispecific antibody M701

A human-mouse chimeric bispecific antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM), with potential immunomodulating and antineoplastic activities. Upon administration, anti-EpCAM/anti-CD3 bispecific antibody M701 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and EpCAM on EpCAM-expressing tumor cells. This activates and redirects CTLs to EpCAM-expressing tumor cells, which results in the CTL-mediated cell death of EpCAM-expressing tumor cells. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.
Synonym:EpCAM x CD3 bispecific antibody M701
Code name:M 701
M-701
M701
Search NCI's Drug Dictionary